Long-Term Assessment of the Safety and Performance of the NuVasive Simplify Disc at Two Levels
Study Details
Study Description
Brief Summary
A prospective, multicenter post-market clinical follow-up study to evaluate the 10-year long-term safety and effectiveness of the Simplify Disc at two levels in subjects who were enrolled in the IDE study (NCT03123549) and/or post approval study (NCT04980378).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Simplify Disc Extended follow-up of subjects treated with the Simplify Disc during IDE study NCT03123549 and followed in the post-approval study NCT04980378. |
Device: NuVasive Simplify Cervical Artificial Disc
Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
|
Outcome Measures
Primary Outcome Measures
- Clinical Composite Success [10 years]
The primary endpoint for individual success is defined as follows: Improvement of the NDI of at least 15 percentage points compared to baseline, and Maintenance or improvement in neurological status, and No serious adverse event classified as implant associated or implant/surgical procedure associated; and No secondary index surgeries by 120 months
Secondary Outcome Measures
- Percentage of subjects meeting the minimal clinically important difference (MCID) for NDI at each annual timepoint [10 years]
Neck Disability Index; scale is reported in a range from 0-100, with 0 consistent with best ability to function and 100 worst ability to function.
- Percentage of subjects meeting MCID for neck and arm pain questionnaire for each of the following pain locations: neck pain, arm pain, left arm pain, right arm pain. [10 years]
Neck and arm pain questionnaire, scale is reported in a range from 0 to 10, with 0 consistent with no pain and 10 with most pain
- Motor status at each annual timepoint compared to baseline [10 years]
A change of one or more grade levels in muscle strength will be regarded as clinically significant.
- Sensory status at each annual timepoint compared to baseline [10 years]
Sensation will be graded as normal or abnormal (diminished or absent). Any changes from abnormal to normal or absent to diminished will be regarded as clinically significant improvement.
- SF-36® Health Survey at each annual timepoint compared to baseline [10 years]
The SF-36 is a multipurpose survey with 36 questions. The questions were combined, scored and weighted to create mental and physical functioning and overall health-related quality of life. Higher scores indicate better outcomes. Scores range from 0-100.
- Dysphagia Handicap Index1 (DHI) at each annual timepoint compared to baseline [10 years]
DHI is scored from 0-100, with a higher score indicative of a less desirable outcome.
- Disc height at each annual timepoint will be compared to baseline [10 years]
Average disc height is calculated as the simple average of the anterior and posterior disc heights
- Adjacent level disc degeneration (ALDD) at each annual timepoint will be compared to baseline [10 years]
ALDD is graded in accordance with definitions adapted from Kellgren and Lawrence: None; Doutbtful;Minimal;Moderate;Severe
- Displacement or migration of the Simplify Disc at each annual timepoint will be compared to the post-op timepoint in the IDE study (NCT03123549) [10 years]
Device migration assesses significant movement of the implant postoperatively. Changes of >3 mm will be considered significant due to the margin of error in radiographic determination of displacement distances.
- Range of motion (ROM) at each annual timepoint compared to baseline [10 years]
Changes in Global Range of Motion will be calculated by subtracting the range of motion measured at one time point from the baseline range of motion. Change in Global Range of Motion will be reported in units of degrees.
- Rate of adverse events attributable to Simplify Disc, or use of additional NuVasive instruments, implants, or technologies at each annual timepoint [10 years]
Number of adverse events related to Simplify Disc or additional NuVasive products
- Patient satisfaction and perceived effect at each annual timepoint [10 years]
Patient questionnaire assessing satisfaction with treatment and perceived effect of treatment. Success for each satisfaction question will be defined as either a "Definitely True" or "Mostly True" response. Success for the perceived effect question will be defined as either a "Completely Recovered," "Much Improved," or "Slightly Improved" response.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject was enrolled in the Simplify Disc IDE (NCT03123549) and/or PAS (NCT04980378) at a participating study site
-
Patient understands the conditions of enrollment and is willing sign an informed consent form to participate in the study
Exclusion Criteria:
-
Subject had an SSI at the index level during the IDE study (NCT03123549) or the PAS (NCT04980378)
-
Subject was withdrawn or withdrew consent to participate in the IDE study (NCT03123549) or PAS (NCT04980378)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Carolina Neurosurgery and Spine Associates | Charlotte | North Carolina | United States | 28204 |
| 2 | Texas Back Institute | Plano | Texas | United States | 75093 |
Sponsors and Collaborators
- NuVasive
Investigators
- Study Director: Kyle Malone, NuVasive
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NUVA.TDR1022